Document is current

Any future updates will be listed below

Comments on the SERAPHINA study assessing the utilization, efficacy, safety, and quality of life of nab-paclitaxel in patients with advanced HER2-negative breast cancer

Crossref DOI link: https://doi.org/10.1007/s00432-025-06292-w

Published Online: 2025-09-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark